CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 121 filers reported holding CTI BIOPHARMA CORP in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $5,237,168 | +757.1% | 871,409 | +751.5% | 0.01% | +600.0% |
| Q2 2022 | $611,000 | +196.6% | 102,333 | +131.9% | 0.00% | +100.0% |
| Q1 2022 | $206,000 | -2.8% | 44,136 | -79.8% | 0.00% | 0.0% |
| Q1 2019 | $212,000 | -68.7% | 218,273 | -76.3% | 0.00% | -80.0% |
| Q4 2018 | $677,000 | +4.5% | 922,655 | +207.6% | 0.01% | +66.7% |
| Q3 2018 | $648,000 | -58.4% | 300,000 | -4.1% | 0.00% | -57.1% |
| Q2 2018 | $1,558,000 | – | 312,916 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 3,904,400 | $3,355,000 | 2.31% |
| BVF INC/IL | 6,929,690 | $5,955,000 | 0.65% |
| CAXTON CORP | 324,452 | $279,000 | 0.32% |
| NEA Management Company, LLC | 3,750,000 | $3,222,000 | 0.23% |
| Orbimed Advisors | 5,000,000 | $4,297,000 | 0.07% |
| Fosun International Ltd | 459,274 | $390,000 | 0.03% |
| Paloma Partners Management Co | 229,800 | $197,000 | 0.00% |
| OXFORD ASSET MANAGEMENT LLP | 127,602 | $110,000 | 0.00% |
| LMR Partners LLP | 54,931 | $47,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 17,495 | $15,000 | 0.00% |